Innovation Forum：Evidence to Impact:From Clinical Evidence to Commercial Progression in the Microbiome Industry |
2026-03-13 09:00-12:00 BFA,Main Hall1/2-B,Level 2 |
Supported by： Evidence to Impact:From Clinical Evidence to Commercial Progression in the Microbiome Industry |
Science·Quality·Sustainability — Translational Practices for Global Microbiome Innovation |
| 2026-03-13 09:00-09:10 Opening Remarks:Why Evidence Matters More Than Ever |
| 2026-03-13 09:10-09:30 Keynote I:From Compliance to Competitive Advantage:How Clinical Evidence Shapes Global Success |
| 2026-03-13 09:30-09:50 The Core Choice of Quality:The Scientific Code of Original Strains and the Boundaries of Industry |
| 2026-03-13 09:50-10:30 Featured Session:CRO 3.0 — Built for the Toughest Clinical and Registration Challenges |
| 2026-03-13 10:30-10:55 Technical Session:From Samples to Insights:Building a Translational Research Infrastructure |
| 2026-03-13 10:55-11:35 Roundtable Meeting:Designing Clinical Studies:Regulatory-Grade Data PlatformsPanelists: |
Consensus Launch:IPA China:Industry Consensus on the Scientific Substantiation and Quality Standards of Probiotic Products |
| 2026-03-13 11:55-12:00 Closing Remarks |
